202 related articles for article (PubMed ID: 15317833)
1. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
[TBL] [Abstract][Full Text] [Related]
2. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
3. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
4. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Guivarc'h PH; Vachon MG; Fordyce D
Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Gustavson LE; Schweitzer SM; Burt DA; Achari R; Rieser MJ; Edeki T; Chira T; Yannicelli HD; Kelly MT
Clin Ther; 2006 Mar; 28(3):373-87. PubMed ID: 16750452
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
8. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects.
Sunkara G; Reynolds CV; Pommier F; Humbert H; Yeh C; Prasad P
Curr Med Res Opin; 2007 Mar; 23(3):631-40. PubMed ID: 17355744
[TBL] [Abstract][Full Text] [Related]
10. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters.
McKenney JM; Swearingen D; Di Spirito M; Doyle R; Pantaleon C; Kling D; Shalwitz RA
J Clin Pharmacol; 2006 Jul; 46(7):785-91. PubMed ID: 16809804
[TBL] [Abstract][Full Text] [Related]
11. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Nov; 64(5):477-83. PubMed ID: 9834039
[TBL] [Abstract][Full Text] [Related]
12. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Zhu T; Awni WM; Hosmane B; Kelly MT; Sleep DJ; Stolzenbach JC; Wan K; Chira TO; Pradhan RS
J Clin Pharmacol; 2009 Jan; 49(1):63-71. PubMed ID: 18952910
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
14. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
15. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP; Keating GM
Am J Cardiovasc Drugs; 2009; 9(6):401-9. PubMed ID: 19929038
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T; Ansquer JC; Kelly MT; Sleep DJ; Pradhan RS
J Clin Pharmacol; 2010 Aug; 50(8):914-21. PubMed ID: 20145261
[TBL] [Abstract][Full Text] [Related]
17. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
18. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
19. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.
Gustavson LE; Schweitzer SM; Koehne-Voss S; Achari R; Chira TO; Esslinger HU; Yannicelli HD
J Clin Pharmacol; 2005 Aug; 45(8):947-53. PubMed ID: 16027406
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
